CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 621 enrolled
Drug / intervention
Cyclosporine 0.010% eye drops +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00991458
NCT00991458Phase 2Completed
CompareCT.gov

Study of Cyclosporine in Post-LASIK Patients

Allergan·interventional·Posted Oct 8, 2009·Updated Jul 11, 2013

In Brief

A Phase 2 clinical trial evaluating Cyclosporine 0.010% eye drops, Cyclosporine 0.005% eye drops, and 1 other intervention for Laser In Situ Keratomileusis. Completed, enrolled 621 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLaser In Situ Keratomileusis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 8, 2009
Enrollment StartOct 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.7 years ago

Interventions

Cyclosporine 0.010% eye dropsdrug

Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

Cyclosporine 0.005% eye dropsdrug

Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

Placebo (Vehicle for Cyclosporine)drug

Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.